CHAPEL HILL, N.C., Feb. 29, 2012 /PRNewswire/ -- Cempra, Inc. (NASDAQ: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Cowen and Company 32nd Annual Health Care Conference at 11:20 a.m. EST, March 6, 2012, at The Boston Marriott Copley Place in Boston. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA ™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).
About Cempra, Inc.Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.
Investor Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC(212) 845-4226 Robert.email@example.comAndreas MarathovouniotisRusso Partners, LLC(212) 845-4235 Andreas.firstname.lastname@example.org Media Contact:Elliot Fox Russo Partners, LLC (212) 845-4253 Elliot.email@example.com SOURCE Cempra, Inc.